Adverum Biotechnologies has completed enrollment in the phase 2 INFINITY trial to evaluate a single injection of ADVM-022 for the treatment of diabetic macular edema, according to a press release.
ADVM-022 may offer a lower treatment burden than frequent, long-term anti-VEGF intravitreal injections. In the phase 1 OPTIC trial, a single in-office intravitreal injection has shown efficacy and safety for upward of 2 years in patients with wet age-related macular degeneration.
“2021 is an exciting year for Adverum as we build on the tremendous progress we have made to advance (Read more...)
Uncategorized